Combining Immunotherapy With Antiangiogenesis in RCC
Toni Choueiri, MD:So, there’s a recent trial that reported on the activity of a VEGF inhibitor, well-tolerated bevacizumab, and a PD-L1 inhibitor atezolizumab in metastatic RCC, a phase III trial against sunitinib. Primary endpoint was investigator-assessed progression-free survival in the PD-L1positive population, and this was met. The regimen was extremely well tolerated, though it’s early to add the regimen and have for it a certain place for many reasons. First, the overall survival is still not mature enough. But this is an interesting and evolving story with a well-tolerated regimen.
The other important consideration with this regimen is that the independent review of the scan didn’t show superiority of the combination over sunitinib. So, I think it’s too early to comment on that regimen, but certainly the follow-ups will be very important on this trial.
Transcript edited for clarity.
Roundtable Roundup: Lung Cancer Molecular Testing and ALK-Targeted Treatment
January 18th 2025In separate, live virtual events, Vincent K. Lam, MD, and Chul Kim, MD, MPH, discuss molecular assays and treatment options for a patient with metastatic non–small cell lung cancer (NSCLC), with participants.
Read More
Amivantamab/Lazertinib Maintains OS Benefit in EGFR+ NSCLC
January 15th 2025During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and toxicity management in patients with EGFR-mutated non–small cell lung cancer in the second article of a 2-part series.
Read More
